Shares of AXT Inc. shifted dramatically higher this week, extending a blistering rally to $64.27 (+6.4% today) as investors continue digesting what may be the most transformative quarter in the company's history. The semiconductor wafer maker — which supplies the specialized crystals used in high-speed optical chips for AI data centers — has nearly doubled from its $36.97 close on July 29, the day before earnings dropped. The question now: does the stock's velocity match the underlying business, or has euphoria outrun the fundamentals?

  • A 171% Earnings Beat Rewrote Wall Street's Models Overnight. Q2 earnings per share came in at $0.19 versus the $0.07 consensus, while revenue of $47.6 million crushed the $34.1 million estimate, driven by record indium phosphide revenue of $30.7 million.

Gross margins surged to 45.0% from just 29.9% the prior quarter , showing that higher production volumes and a richer product mix are dropping straight to the bottom line. The company swung from a net loss of $0.15/share a year ago to $0.19 of profit.

  • The Q3 Guide Stunned Even the Bulls. Management guided Q3 earnings to $0.30–$0.32/share and revenue to roughly $66 million — Street models had been sitting at just $0.10 and $38.81 million. That is not a tweak; it is a wholesale reset of the earnings trajectory. Additional export permits from China could push results even higher, though permit timing remains unpredictable.

  • Locked-In Customers Provide Unusual Visibility for a Materials Company. A long-term deal with optical-component maker Lumentum running through 2031, backed by $87 million in deposits, gives AXT multi-year demand certainty.

Additional strategic supply agreements with Coherent and Casella include prepayments totaling $47.7 million.

Most of the revenue impact from these deals lies ahead, with the Casella agreement not starting until 2027.

  • Capacity Is the Bottleneck — and the Risk. AXT targets roughly $60 million in quarterly indium phosphide capacity by year-end 2026, scaling to $130 million by late 2027.

Crystal growth yields, clean-room expansion, and export permit timing are major operational constraints that could throttle growth. AXT's vertically integrated China operations offer cost advantages but expose it to substantial geopolitical risk from export controls.

At $64, the stock prices in flawless execution. Needham upgraded to Buy at $90; Wedbush reiterated Outperform at $93. Investors betting on sustained AI infrastructure spending have reason for optimism — but the gap between today's price and dependable, permit-dependent production means volatility is far from over.